Feed CKDXF
CK

Ceryvyn Therapeutics Ltd CKDXF · OTC

$0.01 +0.00% (+$0.00)

Summary

38 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 33,082,300 USD is left as net profit.
  • It has no debt and holds $20.8M in cash.
  • The share price is below the Bulios Fair Price.

What to watch

  • Revenue fell by 81% a year over the last 3 years.
  • It reports a profit, yet spends more cash than it brings in.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $0.011
P/E today 0.1
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 0.1 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue fell by 62% a year over 5 years. Over the last 3 years it fell by 81% a year.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It has no debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy